OBJECTIVES: To determine the usefulness of urinary bromotyrosine, a noninvasive marker of eosinophil-catalyzed protein oxidation, in tracking with indexes of asthma control and in predicting future asthma exacerbations in children. STUDY DESIGN: Children with asthma were recruited consecutively at the time of clinic visit. Urine was obtained, along with spirometry, exhaled nitric oxide, and Asthma Control Questionnaire data. Follow-up phone calls were made 6 weeks after enrollment. RESULTS: Fifty-seven participants were enrolled. Urinary bromotyrosine levels tracked significantly with indexes of asthma control as assessed by Asthma Control Questionnaire scores at baseline (R = 0.38, P = .004) and follow-up (R = 0.39, P = .008). Participants with high baseline levels of bromotyrosine were 18.1-fold (95% CI 2.1-153.1, P = .0004) more likely to have inadequately controlled asthma and 4.0-fold more likely (95% CI 1.1-14.7, P = .03) to have an asthma exacerbation (unexpected emergency department visit; doctor's appointment or phone call; oral or parenteral corticosteroid burst; acute asthma-related respiratory symptoms) over the ensuing 6 weeks. Exhaled nitric oxide levels did not track with Asthma Control Questionnaire data; and immunoglobulin E, eosinophil count, spirometry, and exhaled nitric oxide levels failed to predict asthma exacerbations. CONCLUSIONS: Urinary bromotyrosine tracks with asthma control and predicts the risk of future asthma exacerbations in children.
OBJECTIVES: To determine the usefulness of urinary bromotyrosine, a noninvasive marker of eosinophil-catalyzed protein oxidation, in tracking with indexes of asthma control and in predicting future asthma exacerbations in children. STUDY DESIGN:Children with asthma were recruited consecutively at the time of clinic visit. Urine was obtained, along with spirometry, exhaled nitric oxide, and Asthma Control Questionnaire data. Follow-up phone calls were made 6 weeks after enrollment. RESULTS: Fifty-seven participants were enrolled. Urinary bromotyrosine levels tracked significantly with indexes of asthma control as assessed by Asthma Control Questionnaire scores at baseline (R = 0.38, P = .004) and follow-up (R = 0.39, P = .008). Participants with high baseline levels of bromotyrosine were 18.1-fold (95% CI 2.1-153.1, P = .0004) more likely to have inadequately controlled asthma and 4.0-fold more likely (95% CI 1.1-14.7, P = .03) to have an asthma exacerbation (unexpected emergency department visit; doctor's appointment or phone call; oral or parenteral corticosteroid burst; acute asthma-related respiratory symptoms) over the ensuing 6 weeks. Exhaled nitric oxide levels did not track with Asthma Control Questionnaire data; and immunoglobulin E, eosinophil count, spirometry, and exhaled nitric oxide levels failed to predict asthma exacerbations. CONCLUSIONS: Urinary bromotyrosine tracks with asthma control and predicts the risk of future asthma exacerbations in children.
Authors: Wendy C Moore; Eugene R Bleecker; Douglas Curran-Everett; Serpil C Erzurum; Bill T Ameredes; Leonard Bacharier; William J Calhoun; Mario Castro; Kian Fan Chung; Melissa P Clark; Raed A Dweik; Anne M Fitzpatrick; Benjamin Gaston; Mark Hew; Iftikhar Hussain; Nizar N Jarjour; Elliot Israel; Bruce D Levy; James R Murphy; Stephen P Peters; W Gerald Teague; Deborah A Meyers; William W Busse; Sally E Wenzel Journal: J Allergy Clin Immunol Date: 2007-02 Impact factor: 10.793
Authors: Meyer Kattan; Rajesh Kumar; Gordon R Bloomberg; Herman E Mitchell; Agustin Calatroni; Peter J Gergen; Carolyn M Kercsmar; Cynthia M Visness; Elizabeth C Matsui; Suzanne F Steinbach; Stanley J Szefler; Christine A Sorkness; Wayne J Morgan; Stephen J Teach; Vanthaya N Gan Journal: J Allergy Clin Immunol Date: 2010-03 Impact factor: 10.793
Authors: Paul M O'Byrne; Søren Pedersen; Carl Johan Lamm; Wan C Tan; William W Busse Journal: Am J Respir Crit Care Med Date: 2008-10-31 Impact factor: 21.405
Authors: David A Kaminsky; Ashlie A Rice; Michael Bissonette; Teresa Larose; Lisa Phillips; Laura Cohen; Thomas Lahiri; Barbara Frankowski Journal: J Asthma Date: 2008-06 Impact factor: 2.515
Authors: Rebecca S Gruchalla; Hugh A Sampson; Elizabeth Matsui; Gloria David; Peter J Gergen; Agustin Calatroni; Mark Brown; Andrew H Liu; Gordon R Bloomberg; James F Chmiel; Rajesh Kumar; Carin Lamm; Ernestine Smartt; Christine A Sorkness; Suzanne F Steinbach; Kelly D Stone; Stanley J Szefler; William W Busse Journal: J Allergy Clin Immunol Date: 2009-07-16 Impact factor: 10.793
Authors: Suzy A A Comhair; Deepa Grandon; Anam Khan; Renliang Zhang; Stanley L Hazen; Serpil C Erzurum Journal: Am J Respir Crit Care Med Date: 2015-06-01 Impact factor: 21.405
Authors: Elliott Lamkin; Georgiana Cheng; Anthony Calabro; Vincent C Hascall; Eun Ji Joo; Lingyun Li; Robert J Linhardt; Mark E Lauer Journal: J Biol Chem Date: 2015-01-05 Impact factor: 5.157
Authors: Panpicha Sattasathuchana; Naris Thengchaisri; Jan S Suchodolski; Jonathan A Lidbury; Jörg M Steiner Journal: J Vet Diagn Invest Date: 2019-02-15 Impact factor: 1.279
Authors: Zeneng Wang; Joseph A DiDonato; Jennifer Buffa; Suzy A Comhair; Mark A Aronica; Raed A Dweik; Nancy A Lee; James J Lee; Mary Jane Thomassen; Mani Kavuru; Serpil C Erzurum; Stanley L Hazen Journal: J Biol Chem Date: 2016-09-01 Impact factor: 5.157
Authors: Douglas C Cowan; D Robin Taylor; Laura E Peterson; Jan O Cowan; Rochelle Palmay; Avis Williamson; Jef Hammel; Serpil C Erzurum; Stanley L Hazen; Suzy A A Comhair Journal: J Allergy Clin Immunol Date: 2014-12-06 Impact factor: 10.793
Authors: Stanley J Szefler; James F Chmiel; Anne M Fitzpatrick; George Giacoia; Thomas P Green; Daniel J Jackson; Heber C Nielsen; Wanda Phipatanakul; Hengameh H Raissy Journal: J Allergy Clin Immunol Date: 2013-11-28 Impact factor: 10.793